Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577382 · ClinicalTrials.gov registry record · Phase 2
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00577382 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 52 participants.
The verdict
NCT00577382, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. Suninitib is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.
Interventions
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577382
The ClinicalTrials.gov registry entry for NCT00577382 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib is the first listed.
NCT00577382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577382 about?
NCT00577382 is a clinical study titled "SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma". The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. Suninitib is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certa...
What is the current status of trial NCT00577382?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2007-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00577382?
The interventions under investigation include: Sunitinib (DRUG).
Who is sponsoring clinical trial NCT00577382?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.